- Conditions
- HIV Infections
- Interventions
- Cabotegravir Oral Tablet, TDF/FTC tablets, Placebo for TDF/FTC tablets, Placebo for cabotegravir oral tablet, CAB LA, Placebo for CAB LA
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 4,570 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2025
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Los Angeles, California • Oakland, California + 20 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 14,322
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Interventions
- Paclitaxel(intravenous) + Carboplatin(intravenous), Paclitaxel(intravenous) + Carboplatin(intraperitoneal)
- Drug
- Lead sponsor
- Gynecologic Oncology Trial & Investigation Consortium
- Network
- Eligibility
- 20 Years and older · Female only
- Enrollment
- 655 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2021
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Adhesive Capsulitis, Adhesive Capsulitis of Unspecified Shoulder, Frozen Shoulder
- Interventions
- Methylprednisolone Injectable Product, Doxycycline Injection
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Lumbar Spinal Stenosis
- Interventions
- Epidural Steroid Injection with Lavage
- Procedure
- Lead sponsor
- Dallas VA Medical Center
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Diabetic Macular Edema
- Interventions
- Dexamethasone
- Drug
- Lead sponsor
- Lahey Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Peabody, Massachusetts
- Conditions
- Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma, Advanced Colorectal Cancer (Part 1)
- Interventions
- PF-07799933, binimetinib, cetuximab, midazolam, fluorouracil, leucovorin, oxaliplatin
- Drug · Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 31
- States / cities
- Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 13 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Exenatide (AC2993), Insulin glargine
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 551 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 21
- States / cities
- San Diego, California • San Mateo, California • Fort Myers, Florida + 18 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Insulin glargine/Lixisenatide, Insulin glargine (HOE901), Background therapy
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 85
- States / cities
- Montgomery, Alabama • Little Rock, Arkansas • Anaheim, California + 63 more
- Conditions
- Opiate Dependence
- Interventions
- extended release naltrexone
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 146 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Kidney Transplantation
- Interventions
- Alefacept, tacrolimus, basiliximab, mycophenolate mofetil, Corticosteroids
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 323 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 38
- States / cities
- Loma Linda, California • Los Angeles, California • Sacramento, California + 28 more
- Conditions
- Dengue
- Interventions
- TetraVax-DV Vaccine - Admixture TV003, TetraVax-DV Vaccine - Admixture TV005, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2014
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Burlington, Vermont
- Conditions
- Post-operative Excessive Scarring
- Interventions
- Botulinum Toxin, Saline
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Alzheimer Disease, Dementia of Alzheimer Type
- Interventions
- PET/MR Imaging, 64Cu-FBP8
- Diagnostic Test · Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Knee Osteoarthritis
- Interventions
- Hymovis Intra-articular Injection, Phosphate Buffered Saline Injection
- Device · Procedure
- Lead sponsor
- Fidia Farmaceutici s.p.a.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Encinitas, California + 28 more
- Conditions
- Pain, Postoperative
- Interventions
- N1539, Placebo
- Drug
- Lead sponsor
- Baudax Bio
- Industry
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 6
- States / cities
- Florence, Alabama • Mobile, Alabama • Sheffield, Alabama + 3 more
- Conditions
- Psoriasis
- Interventions
- 80 mg Ixekizumab Dosing Regimens 1, 2, and 3, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,296 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Anaheim, California • Bakersfield, California + 31 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- 18F-AraG
- Drug
- Lead sponsor
- University of Tennessee
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- New use of semaglutide injection, New initiation of "standard of care" (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral)
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,316 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Astrocytoma, Glioma, Oligodendroglioma
- Interventions
- Irinotecan Hydrochloride (HCI) Treatment, Continued Irinotecan Hydrochloride (HCI) Treatment
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Hysterectomy, Surgery
- Interventions
- IS-001, da Vinci® Si/Xi Surgical System
- Drug · Device
- Lead sponsor
- Intuitive Surgical
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- El Paso, Texas
- Conditions
- Shoulder Pain
- Interventions
- Tylenol and NSAIDS (Ibuprofen, diclofenac)
- Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Columbia, Maryland
- Conditions
- Sentinel Lymph Node
- Interventions
- ICG Intervention, Near Infrared Imaging
- Drug · Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hypertension, Resistant to Conventional Therapy
- Interventions
- Placebo - 1st Cycle, MANP - 1st Cycle, MANP - 2nd Cycle
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 20 Years to 70 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Sarcoma
- Interventions
- Indocyanine green solution administered at 2.0mg/kg., Stryker SPY-PHI Imaging Device
- Drug · Device
- Lead sponsor
- Kurt Weiss
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania